emtricitabine (emtriva) Report issue

Small molecule Approved FDA Fast Track FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, marketed by Gilead as Emtriva, was first approved by the U.S. Food and Drug Administration in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.   NCATS

Chemistry

  • SMILES: NC1=NC(=O)N(C=C1F)[C@@H]2CS[C@H](CO)O2
  • InChIKey: XQSPYNMVSIKCOC-NTSWFWBYSA-N
  • Mol. Mass: 247.247
  • ALogP: -0.46
  • ChEMBL Molecule:
    emtricitabine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.5528 - $17.4549
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( efavirenz (sustiva), tenofovir (viread), emtricitabine (emtriva) - other name: emtricitabine; tenofovir    disoproxil fumarate; efavirenz )
|
( emtricitabine (emtriva), bictegravir (Biktarvy), tenofovir alafenamide (genvoya) )
|
( tenofovir (viread), emtricitabine (emtriva), rilpivirine (edurant) )
|
( emtricitabine (emtriva), tenofovir alafenamide (genvoya) )
|
( emtricitabine (emtriva), tenofovir alafenamide (genvoya), cobicistat (stribild), elvitegravir (vitekta) - other name: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide )
|
( emtricitabine (emtriva), tenofovir alafenamide (genvoya), rilpivirine (edurant) )
|
( tenofovir (viread), emtricitabine (emtriva), cobicistat (stribild), elvitegravir (vitekta) - other name: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate )
|
( emtricitabine (emtriva), darunavir (prezista), tenofovir alafenamide (genvoya), cobicistat (stribild) )
|
( tenofovir (viread), emtricitabine (emtriva) - other names: emtricitabine and tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate 200 mg-245 mg oral tablet [truvada], immediate intervention arm truvada in brazil, tenofovir (300mg)/emtricitabine(200mg) [truvada®], tenofovir disoproxil fumarate; emtricitabine, tenofovir disoproxyl fumarate 300 mg plus emtricitabine 200 mg oral tablet )

Alternative names

1-(2-(hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine | 2',3',5-ftc | 2',3'-dideoxy-5-fluoro-3'-thiacytidine | 2',3'-dideoxy-5-fluoro-3'-thiacytidine, (2s-cis)-isomer | 2'-deoxy-5-fluoro-3'-oxa-4'-thiocytidine | (-)-2'-deoxy-5-fluoro-3'-thiacytidine | 2'-deoxy-5-fluoro-3'-thiacytidine | 2'-deoxy-5-fluoro-3'-thiacytidine, 2s-trans isomer | 2'-deoxy-5-fluoro-3'-thiacytidine, cis-isomer | 2-ftc | (-)-(2r,5s)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine | (2r-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone | 4-amino-5-fluoro-1-((2r,5s)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1h-pyrimidin-2-one | 4-amino-5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1h)-one | 524w91 | 5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine | 5-fluoro-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine | (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine | bw524w91 | bw 524w91 | bw-524w91 | (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one | coviracil | descovy | dotfc | efavirenz / emtricitabine / tenofovir disoproxil fumarate | efavirenz / emtricitabine / tenofovir disoproxil maleate | efavirenz / emtricitabine / tenofovir disoproxil, phosphate | efavirenz / emtricitabine / tenofovir disoproxil succinate | elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate | emtricitabin | emtricitabina | emtricitabine | emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide | emtricitabine / rilpivirine hydrochloride /tenofovir disoproxil fumarate | emtricitabine / tenofovir | emtricitabine / tenofovir alafenamide | emtricitabine / tenofovir disoproxil fumarate | emtricitabine / tenofovir disoproxil maleate | emtricitabine, tenofovir disoproxil phosphate | emtricitabine / tenofovir disoproxil succinate | emtricitabinum | emtricitabline | emtricitagine | emtriva | ftc | (-)-ftc | ftc-(-) | racivir

Organizations (370)

Research & Development (357)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (75)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (75)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Aicardi Syndrome (Phase 1/Phase 2)

AIDS-Related Opportunistic Infections (Phase 4)

Alcohol-Induced Disorders (Phase 4)

Alveolar Bone Loss (Phase 4)

Alzheimer Disease (Phase 1)

Analgesics, Opioid (Phase 4)

Antiretroviral Therapy, Highly Active (Phase 4)

Art (Phase 4)

Behavior and Behavior Mechanisms (Phase 1/Phase 2)

Bone Diseases (Phase 4)

Bone Diseases, Metabolic (Phase 4)

Breast Feeding (Phase 3)

Buprenorphine (Phase 4)

Cardiovascular Diseases (Phase 4)

Central Nervous System (Phase 2)

Cognition Disorders (Phase 4)

Cognitive Dysfunction (Phase 1)

Coinfection (Phase 4)

Contraception (Early Phase 1)

Coronary Artery Disease (Phase 4)

Coronavirus Infections (Phase 3)

COVID-19 (Phase 3)

Depression (Phase 4)

Drug Misuse (Phase 4)

Drugs, Investigational (Phase 2/Phase 3)

Estrogens (Phase 4)

Fibrosis (Phase 4)

Gender Identity (Phase 1/Phase 2)

Harm Reduction (Phase 4)

Health Personnel (Phase 3)

Healthy Volunteers (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis B virus (Phase 2)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

HIV Seropositivity (Phase 3)

Hormones (Phase 4)

Insulin Resistance (Phase 1)

Kidney Diseases (Phase 4)

Kidney Transplantation (Phase 4)

Leukoencephalopathy, Progressive Multifocal (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Maintenance (Phase 4)

Malaria (Phase 3)

Medication Adherence (Phase 4)

Menopause (Phase 4)

Methadone (Phase 4)

Opioid-Related Disorders (Phase 4)

Organ Transplantation (Phase 4)

Osteoporosis (Phase 4)

Parasitic Diseases (Phase 1/Phase 2)

Patient Compliance (Phase 4)

Pre-Exposure Prophylaxis (Phase 4)

Pregnancy (Phase 4)

Proteinuria (Phase 4)

Quality of Life (Phase 4)

Respiratory Tract Infections (Phase 1/Phase 2)

Risk Reduction Behavior (Phase 4)

Risk-Taking (Phase 4)

Sarcoma, Kaposi (Phase 4)

SARS-CoV-2 (Phase 2/Phase 3)

Sexual Behavior (Phase 4)

Sexually Transmitted Diseases (Phase 4)

Sleep Disorders, Intrinsic (Phase 4)

Sleep Wake Disorders (Phase 4)

Substance-Related Disorders (Phase 4)

Syphilis (Phase 4)

Transgender Persons (Phase 4)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 479
  • # of Trial Organizations: 357

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue